2026 European Hematology Association (EHA) Meeting

Benefit of Rusfertide Maintained in Patients (Pts) With Low-Risk or High-Risk Polycythemia Vera (PV): Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study García-Gutiérrez G, et al Impact of Rusfertide on Polycythemia Vera (PV)-Related Symptoms and Patient-Reported Outcome-Related Items in the Randomized, Double-Blind Phase 3 VERIFY Study Lucchesi, A, et al Effect of Rusfertide on Cytoreductive Therapy Use in Patients with Phlebotomy Dependent Polycythemia Vera: Post Hoc Analysis from the Randomized Controlled Phase 3 VERIFY Study Palandri, F, et al Thrombo